Research Activities
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam.
Based on the data in the PROGNOSIS registry, it is planned to establish further basic research-oriented and translational projects.
Through intensive research activities, the subject of NCFB should also increasingly play a role at German congresses.
Professor Dr. Tobias Welte and Dr. Felix Ringshausen, both from Hannover Medical School, are the German representatives participating in the ERS Task Force to develop a European guideline: the ERS Clinical Practice Guideline for the Management of Bronchiectasis.
The translation and commentary for the German language trinational (AT-CH-DE) guideline is being planned.
Publications in German language
Raidt, J., Brillault, J., Brinkmann, F., Jung, A., Koerner-Rettberg, C., Koitschev, A., Linz-Keul, H., Nüßlein, T., Ringshausen, F. C., Röhmel, J., Rosewich, M., Werner, C. and Omran, H.
Pneumologie (Nov 2020)
Lommatzsch, M., Rabe, K. F., Taube, C., Joest, M., Kreuter, M., Wirtz, H., Blum, T. G., Kolditz, M., Geerdes-Fenge, H., Otto-Knapp, R., Häcker, B., Schaberg, T., Ringshausen, F. C., Vogelmeier, C. F., Reinmuth, N., Reck, M., Gottlieb, J., Konstantinides, S., Meyer, F. J., Worth, H., Windisch, W., Welte, T. and Bauer, T.
Pneumologie (Nov 26 2020)
Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele-Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., Fischer, R., Grosse-Onnebrink, J., Hammermann, J., Hebestreit, H., Hogardt, M., Hugel, C., Hug, M., Illing, S., Jung, A., Kahl, B., Koitschev, A., Mahlberg, R., Mainz, J. G., Mattner, F., Mehl, A., Moller, A., Muche-Borowski, C., Nusslein, T., Puderbach, M., Renner, S., Rietschel, E., Ringshausen, F. C., Schmidt, S., Sedlacek, L., Sitter, H., Smaczny, C., Tummler, B., Vonberg, R., Wielputz, M. O., Wilkens, H., Wollschlager, B., Zerlik, J., Duesberg, U. and van Koningsbruggen-Rietschel, S.
Pneumologie (May 2018)
Rademacher, J., Buck, A., Schwerk, N., Price, M., Fuge, J., Welte, T. and Ringshausen, F. C.
Pneumologie (Aug 2017)
Ringshausen FC, Rademacher J.
Internist (Berl). 2016;57(2):142-52
Rademacher J, Ringshausen FC.
COPD in Deutschland. 2015 Aug; 50-52
Rademacher J, de Roux A, Ringshausen FC.
Pneumologie. 2015 Jul;69(7):391-3
Rademacher J, Schweigert M.
Zentralbl Chir. 2015 Feb;140(1):113-26; quiz 127-8
Ringshausen FC, Rademacher J, Welte T.
Dtsch Med Wochenschr. 2014 Apr;139(14):707-10
Rademacher J, Ringshausen FC.
Pneumologie. 2013 Jan; 67(1):40-7; 48-9
Rademacher J, Welte T.
Dtsch Arztebl Int. 2011 Dec;108(48):809-15
Ringshausen FC, Welte T.
Der Pneumologe. 2014/4
Rademacher J, Ringshausen FC.
Pneumologe. 2014/4
Dr. N. Derichs.
Pneumologe. 2014/4
BrĂĽckner U.
Pneumologe. 2014/4
Glöckl R, Kenn K.
Pneumologe. 2014/4
Flick H, Meilinger M, Wagner M, Olschewski H, Eber E.
Pneumologe. 2014/4
de Roux A.
Pneumologe. 2014/4
Current Studies
Up to now, only a few controlled studies have been performed, so that hardly any evidence-based recommendations could be submitted for non-CF bronchiectasis.
At the present time, the efficacy of many different substances is being tested. A hypertonic saline solution is often used clinically as it has been shown to be effective in CF, although this has not yet been documented for non-CF bronchiectasis.
After good results in the Phase II studies, inhalational mannitol is now in Phase III clinical trials.
Inhalational antibiotics could be of importance, particularly in patients populated with gram-negative bacteria. Tobramycin and colistin are well established – though not registered – aztreonam, ciprofloxacin and gentamicin are being tested in clinical studies. Macrolides, however, according to the results of several studies with only small sample size, seem to have an additional effect. Long-term therapy with inhalational antibiotics and/or macrolides is only indicated if a clearly positive effect (decreased amount of sputum, no exacerbation) is achieved within three months from start of therapy.
ERADICATE-STUDIEFor Doctors
Taking care of frequently exacerbating patients
An interview with Dr. Felix C. Ringshausen and Prof. Dr. Tobias Welte (in German)